Participated · Series B · Jan 2026

EpiBiologics is a San Mateo–based biotechnology company pioneering the degradation of disease-driving extracellular membrane and soluble proteins via its proprietary EpiTAC bispecific antibody platform. The company’s lead candidate, EPI-326, is designed to degrade all oncogenic forms of EGFR in a tumor-selective manner, aiming to overcome safety and resistance limitations of current EGFR therapies. Preclinical data show strong, durable efficacy with favorable safety and pharmacokinetic profiles, supporting both monotherapy and combination use across multiple cancer types. EpiBiologics plans to commence a first-in-human trial of EPI-326 in early 2026 for non-small cell lung cancer and head and neck squamous cell carcinoma. Proceeds from its recent financing will also expand a broader pipeline in oncology and immunology while bolstering internal capabilities. The company recently strengthened its leadership team by hiring Eric Humke, M.D., Ph.D., as Chief Medical Officer and Aaron Mishel as Chief Financial Officer, and added several industry leaders to its Board.

Participated · Series B · Dec 2023

Seismic Therapeutic uses its proprietary IMPACT machine learning platform to design and optimize biologics for immunology. Its preclinical pipeline is led by two programs: S-1117, a pan‑IgG protease sculpting (IgSc) enzyme candidate, and S-4321, a PD‑1 agonist:FcγRIIb‑selective Dual‑cell Bidirectional (DcB) antibody candidate. The company integrates machine learning with protein engineering, structural biology, and translational immunology to parallelize discovery and simultaneously optimize function, immunogenicity, and developability. Proceeds from the recently closed Series B will advance both lead programs through Phase 1 proof-of-mechanism trials, expand the pipeline in the IgSc and DcB areas, and further develop the IMPACT platform with additional methods. Seismic has advanced two programs into IND‑enabling studies since its Series A and is backed by a broad syndicate of life‑science investors. The company is located in the Boston/Cambridge biotechnology hub. Seismic Therapeutic develops biologic therapeutics for autoimmune diseases by fully integrating machine learning with structural biology, protein engineering and translational immunology via its IMPACT™ platform. The IMPACT platform parallelizes interdisciplinary components of drug discovery to design and analyze vast numbers of proteins in parallel, optimizing both function and developability. The company has an emerging pipeline of novel biologics targeting dysregulated adaptive immunity, including two lead programs—one for Ig-mediated autoimmunity and one for cell-mediated autoimmunity. Seismic launched with a $101 million Series A to fund advancement toward the clinic of those lead programs and to continue building its proprietary platform. The team includes drug developers, machine learning innovators, and academic founders with expertise in immunology, structural biology and protein engineering. Seismic is based in the Boston/Watertown, Mass. biotechnology hub.

Participated · Equity · Sep 2023

AIRNA develops RNA‑editing medicines using a proprietary platform founded on academic research to precisely edit target RNA for both rare and common diseases. Its lead program, AIR‑001, is designed to repair the most common harmful SERPINA1 (PiZ) mutation in alpha‑1 antitrypsin deficiency (AATD) to restore functional M‑AAT production, with subcutaneous dosing and a focus on potency, durability, and safety. The company plans to file a clinical trial application for AIR‑001 in 2H 2025 and advance the candidate into a Phase 1/2 study. Proceeds from the recent financing will also fund development of a pipeline targeting cardiometabolic and other diseases by introducing beneficial genetic variants or repairing harmful ones. AIRNA cites research origins from University of Tübingen and Stanford co‑founders and maintains headquarters in Cambridge, MA, with research operations in Tübingen, Germany. AIRNA is developing RNA editing therapeutics via its RESTORE+ platform, which optimizes oligonucleotide sequence, chemistry, and delivery for precise RNA editing. Its lead product candidate is positioned as a potential best-in-class treatment for alpha-1 antitrypsin deficiency (AATD). The company is advancing a pipeline of candidates to address multiple diseases with high unmet need. AIRNA plans to bring its first drug candidate to the clinic next year and will use Series A proceeds to advance that program and further develop the platform. The company launched with backing from ARCH Venture Partners based on research by academic co-founders Thorsten Stafforst and Jin Billy Li. AIRNA is headquartered in Cambridge, MA, with research operations in Tübingen, Germany, and has raised a total of $90 million in Series A funding. AIRNA emerged from stealth to develop a new class of RNA editing therapeutics built on its RESTORE+ platform, which programs oligonucleotides to recruit endogenous ADAR for precise RNA modifications. The company’s scientific founders were among the first to publish ADAR-mediated RNA editing and the use of oligonucleotides to recruit endogenous ADAR for targeted editing. AIRNA is advancing a pipeline of candidates by optimizing sequence, chemistry, and delivery to achieve precise, efficient, and safe RNA editing. Its initial development program is a candidate to treat the inherited genetic disease alpha-1 antitrypsin deficiency (AATD), and the company is pursuing additional proprietary programs for prevalent diseases with high unmet need. AIRNA says its approach enables medicines that can be conveniently re-dosed and manufactured for large patient populations. The company is headquartered in Cambridge, MA, with research operations in Tübingen, Germany.

Participated · Series A · Nov 2022

Bonum Therapeutics is a privately held company focused on a platform of allosterically regulated, conditionally active therapeutics that combine an antibody-binding sensor domain with a therapeutic domain to become active only when the sensor binds its target. The company is initially concentrating on regulated immunocytokines, including IL-12, IFN-alpha, and TGF-beta for immuno-oncology, while seeking collaborators to apply the technology in other disease areas. Bonum is a spinout of Good Therapeutics, and the entire Good Therapeutics team joined the new company. The platform was validated by Roche’s August 2022 acquisition of Good Therapeutics for $250 million upfront plus potential milestone payments. Bonum raised $93 million in a Series A to advance its regulated cytokine programs and broaden applications of the platform. The company is backed by investors including Codon Capital, Roche Venture Fund, Rivervest Venture Partners, 3x5 Partners, Digitalis Ventures, and Vivo Capital.

Participated · Series A · Apr 2022

Ansa Biotechnologies is a DNA synthesis company based in Emeryville, CA that focuses on producing sequence-perfect clonal DNA and sequence-verified linear double-stranded DNA fragments. Its platform aims to give scientists rapid, accurate access to synthetic DNA for applications across healthcare, life sciences, and other industries. To reinforce reliability, the company recently launched the Ansa On-Time Guarantee, promising that any order not shipped in full and on time will be provided free of charge. It has also rolled out a new pricing framework targeting low-complexity DNA sequences to make routine orders more cost-effective. With its latest capital infusion, Ansa plans to expand U.S. manufacturing capacity, deepen customer-experience initiatives, and strengthen strategic partnerships while advancing its technology stack. Although no revenue or user figures were disclosed, the firm’s continued fundraising indicates growing market traction and operational scaling needs.